Acetyl-L-Carnitine Supplementation During HCV Therapy With Pegylated Interferon-α2b Plus Ribavirin
Status:
Completed
Trial end date:
1997-10-01
Target enrollment:
Participant gender:
Summary
To assess the effects of Acetyl-L-Carnitine administration on work productivity, daily
activity, and fatigue in subjects with chronic hepatitis C treated with
Pegylated-Interferon-α2b and Ribavirin.